VRK-IN-1, 10 mM in DMSO manufacturers
- VRK-IN-1
-
- $100.00
-
2026-06-02
- CAS:2378855-09-3
- Purity: 99.18%
- Supply Ability: 10g
|
| | VRK-IN-1, 10 mM in DMSO Basic information |
| | VRK-IN-1, 10 mM in DMSO Chemical Properties |
| Boiling point | 400.2±40.0 °C(Predicted) | | density | 1.436±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO : 100 mg/mL (286.30 mM; Need ultrasonic) | | pka | 5.78±0.25(Predicted) | | form | Solid | | color | White to off-white | | SMILES | FC1=CC(C2=CN=C(C)C(C3=CC(F)=C(O)C(F)=C3)=C2)=CC(F)=C1O |
| | VRK-IN-1, 10 mM in DMSO Usage And Synthesis |
| Uses | VRK-IN-1 is a potent and selective inhibitor of vaccinia-related kinases 1 (VRK1), with an IC50 of 150 nM. VRK1 is human Ser/Thr protein kinases associated with increased cell division and neurological disorders[1]. | | Biological Activity | VRK-IN-1 is a potent and selective inhibitor of vaccinia-related kinases 1 (VRK1), with an IC50 of 150 nM. VRK1 is human Ser/Thr protein kinases associated with increased cell division and neurological disorders[1].
VRK-IN-1 binds to VRK1-FL by enthalpy-driven, with a Kd of 190 nM[1].VRK-IN-1 (0.4-25 μM; 24 h) slightly decreases the viability of human HeLa cells at the concentration of 3.2 μM[1]. | | References | [1]. Serafim RAM, et, al. Development of Pyridine-based Inhibitors for the Human Vaccinia-related Kinases 1 and 2. ACS Med Chem Lett. 2019 Aug 19;10(9):1266-1271. |
| | VRK-IN-1, 10 mM in DMSO Preparation Products And Raw materials |
|